MedTrace Logo

Using 32 - Gauge Needles With Lengths of 5 mm and 8 mm on Pain Post-injection, Leak and Blood Glucose

NCT04460092 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-07-07

No results posted yet for this study

Summary

This is a Clinical crossover trial study. In this study, 100 patients with type II diabetes will be selected based on entry and exit criteria, then randomly divided into two equal groups (group "A" and group "B").In the first three days of the first week of hospitalization, in group "A" insulin injection with a 90-degree angle and using Nidel 32-Gauge with a length of 5 mm, and in the other group insulin injection with a 90-degree angle and using Nidel 32-Gauge with a length of 8 mm will be done. After a one-day break, in another three days, the types of needles used in the two groups are moved together. After a one-day break, in another three days, the types of needles used in the two groups are replaced together. Then the VAS scale will be used to assess post-injection pain; the amount of leakage after the injection will be measured in two ways Yes/No, according to the researcher's observation. And to check the effect of Needles on controlling patients' blood sugar, their blood sugar levels will be measured based on the routine of hospital units.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

5-mm 32-gauge Insulin needles in the first three days of Intervention

32-gauge needles with a length of 5mm to inject insulin in first three days

DEVICE

8-mm 32-gauge Insulin needles in the first three days of Intervention

32-gauge needles with a length of 8mm to inject insulin in first three days

DEVICE

5-mm 32-gauge Insulin needles in the last three days of Intervention

32-gauge needles with a length of 5mm to inject insulin in second three days

DEVICE

8-mm 32-gauge Insulin needles in the last three days of Intervention

32-gauge needles with a length of 8mm to inject insulin in second three days

Sponsors & Collaborators

  • Baqiyatallah Medical Sciences University

    lead OTHER

Principal Investigators

  • Esmail Heidaranlu · Baqiyatallah Medical Sciences University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-25
Primary Completion
2020-06-29
Completion
2020-09-25

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04460092 on ClinicalTrials.gov